Microbion Corporation

Pharmaceutical ManufacturingMontana, United States11-50 Employees

At Microbion, we are developing a new class of therapeutic drugs to tackle the unmet needs of rare, chronic, and serious diseases. Our lead drug candidate, pravibismane, is a first-in-class therapeutic with a novel triad of activities: anti-infective, antibiofilm, and anti-inflammatory. These synergistic properties uniquely position pravibismane to address conditions where conventional treatments often fail.

We are advancing multiple pravibismane formulations through clinical development, focusing on indications with significant unmet needs:
- Topical pravibismane for diabetic foot ulcers/infections: Phase 3 studies planned for 2025 
- Local/surgical pravibismane for orthopedic infections: Phase 2a studies completed
- Inhaled pravibismane for pulmonary diseases including Nontuberculous mycobacteria lung infections: Ready for first-in-human Phase 1 studies 

Pravibismane has been granted FDA Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations, underscoring its disruptive potential. 

To date, pravibismane development has been supported by over $22M in grants awarded from leading organizations, including the U.S. Department of Defense, NIH, CARB-X, and the Cystic Fibrosis Foundation.

We are actively seeking strategic licensing and development partners to advance Phase 3 trials, explore new indications (e.g., immunomodulation and inflammation), and bring pravibismane to patients worldwide.

Sign up for free to view info

Email Format Employee directory